- March 2019
- December 2018
- June 2018
- January 2018
- December 2017
- October 2017
- June 2017
- April 2017
- February 2017
- January 2017
- December 2016
- September 2016
- August 2016
- June 2016
- March 2016
- February 2016
- January 2016
- December 2015
- October 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- February 2014
- January 2014
- December 2013
- November 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
Category Archives: Stone’s Pharmasave
The holidays can increase the consumption of two drugs that we may use in a light to moderate fashion during the year, either at separate occasions or concurrently. One of these drugs is alcohol and the other is acetaminophen. Sometimes the consumption of alcohol results in adverse effects that require the use of the second drug, or perhaps the acetaminophen is just used regularly for any type of chronic or acute pain you may be experiencing.
The two main organs in our body that help to remove drugs are the liver and the kidneys. A series of chemical reactions occur where drugs are changed or “metabolized” to make them readily removed from the body, often through the intestines or the urinary tract. Without these organs, most drugs would quickly reach toxic levels, resulting in death. We are constantly bombarded with online offers to “boost” the detoxifying powers of both organs to improve health – a concept completely unproven and a certain red flag for someone looking to detox your money from your wallet.
It is common knowledge that alcohol is metabolized for removal from the body largely by the liver. Repeated over-consumption of alcohol, especially over the long term, can lead to liver disease. Acetaminophen is also heavily metabolized by the liver, and large doses of this drug, even in a single dose can have devastating effects on this organ. For the most part, in the average healthy individual, light to moderate intake of alcohol will not cause damage to the kidneys or the liver. The same holds true for acetaminophen in regular doses of 3000-4000 mg per day, even for extended periods of time. In fact we often see studies that seem to indicate that light consumption of alcohol can have some benefits. Keep in mind that this should never be a reason to start consuming alcohol in any amount when you never were before though as alcohol does have some adverse effects on the GI tract associated with it.
Recent evidence however has determined that the consumption of acceptable levels of both of these drugs at the same time can and has lead to serious kidney disease in otherwise healthy people. The effect was of greater probability in older adults (who often have reduced kidney function), males, blacks and Hispanics (over white patients), and those with conditions that can typically reduce kidney function like diabetes, high blood pressure and obesity. This news can come as a shock to those in the medical community who automatically look toward the liver as the weakest link in the metabolism chain for these two drugs. In fact I regularly tell patients to avoid acetaminophen in “hangover” situations as there have been documented cases of liver damage when the two have been taken together. It turns out, that life threatening kidney damage can occur even in the absence of liver disease when they are combined.
The recognized risk is that there is a two-fold increase in kidney dysfunction when these two drugs are combined even at acceptable doses. Keep in mind that many combination products in the over the counter section of the pharmacy contain acetaminophen, including cough and cold and sleep products. There is an increased danger when these medications are consumed and not reported to your pharmacist at the time you are purchasing them. You may be taking acetaminophen already in a prescription product that is combined with an over the counter medication containing the same ingredient. Some patients may also metabolize acetaminophen at a significantly slower rate than others, magnifying the problem. Changing your pain reliever to an anti-inflammatory (NSAID) like ibuprofen or ASA may be no better after alcohol consumption as the increase in inflammation in the lining of the GI tract can result in a serious GI bleed. Using codeine for pain relief is never recommended with alcohol on board.
The take away message here is if you are someone that is taking acetaminophen (or an NSAID or codeine) for pain, you are better off avoiding alcohol consumption even in light amounts. If you are someone with chronic or acute pain to the degree that one of these medications is needed, remember that the adverse effects can be quite sudden rather than gradual, and the use of lower dosages as recommended.
I have seen many changes happen to pharmacy in the last 24 years. One of the most career-shifting has been the change in the reimbursement model that has forced pharmacy to revisit how it makes money to remain afloat while continuing the important work of patient care. The traditional work I am referring to is not something that carries the business for most independent pharmacies.
Even before this adjustment to our financial model, we were criticized for not charging for other everyday services. Now, not only are many of us leaving money on the table for uncharged services that would easily have been charged by other professions and accepted by the public, but we are charging for dispensary services in unsustainable ways that fail to reimburse the business. Specialty services like methadone, travel clinics, injections, med reviews, compounding, nursing home filling, and others have helped relieve some of the financial strain on some pharmacy businesses. Some day soon I am sure medical marijuana will be one of those services.
Take two of these programs: methadone and medical marijuana. One currently runs in many Canadian pharmacies and one is on the horizon. Both of these have and will continue to gain popularity for the pain patient that has been prescribed opioids. In the case of methadone, it becomes a specialty rescue plan to give the patient back at least a small part of normalcy, even if there is no projected hard endpoint in sight. It can allow patients to stay off of street drugs and steer away from opioid addiction, and in addition keep their family, hold a job (at least one that allows them to go for a witnessed ingestion daily), keep some financial stability and make plans for the future. While this system has its share of abusers, the theory is sound.
In the case of medical marijuana, we try to remove opioids in a less proven method perhaps, and use a CBD/TCH combination to deal with pain in a way that has shown to work, even though we still have much to learn about long-term effects. Compounding can be included here as well, as studies have demonstrated and I have personally seen a regular pattern of reduced oral medications for pain when topical compounded products are introduced.
These demonstrate a practise we have shown in modern medicine for “a pill for every ill.” This is your symptom so this is your medication. In our defense we do try to project wellness campaigns into our profession surrounding eating right and physical activity—both with huge potential benefits. We actively run screening programs for cholesterol and blood glucose—again, often in free clinic formats without much evidence to back up clinical outcomes, such as death rate or disease prevention. This is all in the hope of reminding people to think about their health.
We have all pursued prevention programs in our pharmacies in one way or another. I removed sugary beverages a few years ago (a public health campaign that still resonates with my store today). I filmed a 40-minute healthy grocery shopping tour for YouTube for anyone to watch for free, and I have also done the blood pressure and glucose/cholesterol clinics in my store. In an era where evidence-based practitioners are claiming random screening in healthy populations proves questionable benefit, we push on despite costs to our businesses in both time and money.
What about the patient with either an acute need for a strong pain reliever or the one who is the long-term pain patient? You must be living under a rock if this hasn’t caused you to stop and think about where this patient will be in a few years (especially if they are not handled properly by both you and their doctor). Every time you fill a methadone prescription should make you think even harder. Why do we go through the trouble to screen for other diseases and prevent health complications while at the same time filling an opioid prescription while thinking “is this patient early for their refill?” Most of us have spent more time talking to a diabetic patients about their health than an oxycodone user about where their health is going. Is the potential impact of where that opioid patient could be headed any less drastic than the diabetic patient if not monitored properly? Even the patient on regular naproxen is probably not on our radar as someone who may get switched to an opioid and develop misuse issues down the road.
There are many responsible narcotic users out there who just don’t seem to be heading for any addiction or misuse problems. These patients are no less important when it comes to our vigilance though. We have tools available to us to help screen out those who are more likely to misuse. None of these tools are scientifically proven but they are based on our experience with various patient groups with opioids.
Realistically, any pain patient requires more time than the average patient even from day one. As specialized as methadone is today, it has become a regular fill commodity where a hundred or more patients come in for a witnessed ingestion and leave. With these numbers, there isn’t much time for a ”sit down” with each and every one. In stores with a more realistic number of patients, such as 10-20, it is conceivable that pharmacy staff is able to discuss how therapy is going each time, if they are showing subtle signs of drug use. A more one-on-one environment that isn’t rushed might bring out other signs of sub par therapy, drug diversion and other misuse.
If third-party payers reimbursed for such a specialized service, it would improve health outcomes in the long run. Each patient should be interviewed with each renewal of their opioid and as an initial consultation. Pharmacists are in the best place to detect misuse. A patient that is yawning or restless in front of you, or perhaps agitated during the med review, may be showing signs of withdrawal from an opioid and could be a patient who is taking other sources of opiates along with their prescription. Urine drug testing should be discussed as a possibility early on with treatment as well so that it doesn’t offend patients later on when they are suspected of misuse.
It is estimated that 22% of patients will discontinue opioid therapy due to side effects. This may involve dose-limiting side effects that would require a dose reduction or even a discontinuation of the medication. This may include sedation, which should be assessed with high opioid doses (especially more than 200mg oral morphing equivalents) and with each dose increase. Although this will often resolve itself with tolerance, if suspected it should be monitored closely. Asking a patient to return to the pharmacy within a few hours after a dose may help.
Cognitive dysfunction follows the same warnings of dose increase and high dose as with sedation but can be trickier to pick out unless you take time to speak to the patient for a few minutes. It involves cloudy thinking, poor memory and diminished concentration. As with sedation, reducing the dose, discontinuing the drug or opioid rotation can help. Opioid-induced hyperalgesia is a side effect where this specialty service proves its worth. Again it tends to occur at higher doses and is a phenomenon where the pain threshold seems to drop, giving an increased sensitivity to pain as the opioid dose increases. Instead of a knee jerk increase in opioid dose, the dose should actually be tapered or a COX-2 inhibitor can be given concurrently. It has also been recommended that an NMDA receptor antagonist like Ketamine be tried. Quite often this molecule is used in our pain compounding.
A potentially serious side effect that can occur with opioids is sleep apnea, possibly due to the effect on sleep architecture. This may affect up to 30% of all patients on chronic opioid therapy and can significantly exacerbate a pre-existing sleep apnea condition. This is why it can be helpful for the partner of the patient to come with them to the interview with each fill. Extra information may be gleaned from this type of environment. Respiratory depression is a commonly known side effect of opioid use, however tolerance develops rather quickly and is often a problem only with patients with pulmonary disease like COPD or asthma. It can result in limiting the dose in these patients especially at higher doses.
Constipation, nausea, vomiting, dry mouth, pruritis, urinary retention, myoclonus, hormonal effects, immune suppression, and weight gain/sugar craving are all important side effects that should be addressed and monitored. It is difficult to do all of this with a typical prescription handout at the counter. Of course, the most important effect to monitor is addiction. Although the risk of this is low, it is still a real possibility and constant vigilant monitoring is important to cover your bases.
Tapering doses has become popular with recent warnings to keep patients below 90 oral morphine equivalents. The 2017 Canadian Guideline for Opioids for Chronic Non-Cancer Pain strongly recommends a coordinated multidisciplinary collaboration approach that involves several health professionals that are readily accessible to the physician. The Nova Scotia College of Pharmacists’ registrar Bev Zwicker released a communication to its members on June 26 explaining that the College of Physicians and Surgeons of Nova Scotia warning that the tapering of opioids needs to be done sensitively, collaboratively and with realistic expectations. It also confirmed that rapid withdrawal could be dangerous if done too quickly and that these high- -dose patients cannot be abandoned. These guidelines need to be reviewed by all involved especially pharmacists. Tapering should be considered if there are dose-limiting side effects that are intolerable, if the opioid trial is failed, if the pain has resolved itself, or if there is evidence of addiction or diversion. Most of these tapers are voluntary but the decision may be made by the physician unilaterally. Assessing the patient during the taper requires close monitoring for withdrawal symptoms.
This year, The Journal of the American Pharmacist Association published a paper where a pharmacist-led opioid exit plan for acute postoperative pain management can have benefits when involved at the point of admission, during the post operative recovery period and on discharge. A 2013 BMJ Open paper outlined an RCT where regular GP care was compared to pharmacist-led management of chronic pain and demonstrated improved pain outcomes with the pharmacist-led management.
A 2014 study involving a pharmacist-initiated intervention trial in osteoarthritis showed that patients experience quantifiable benefits from interprofessional collaboration among pharmacists, physicians and physiotherapists. We have also seen pharmacists’ involvement in the co-management of acute pain and substance use disorder improves patient safety and pain control.
Creating your own niche market where you are the go to pharmacy for beneficial outcomes in acute and chronic pain patients becomes key where you are trying to prevent opioid misuse and abuse. It starts with one on one time with the pharmacist and patient each time they come into your pharmacy. It can make your pharmacy the safe place for patients, from their initial prescription for pain to managing a chronic condition while avoiding addiction. Hopefully a patient or their third-party plan would pay for that service.
Ware et al CMAJ 2010; 182(4)
AMN The Prescribing Course—Safe Opioid Prescribing for Chronic Non-Cancer Pain 1st Ed Oct 2014 MacDougall/Fraser
Bruhn H, Bond CM, Elliott AM, et al. Pharmacist-led management of chronic pain in primary care; results from a randomized controlled exploratory trial. BMJ Open 2013;3:e002361
Marra, CA et al Cost-Utility Analysis of a Multidisciplinary Strategy to Manage Osteoarthritis of the Knee: Economic Evaluation of a Cluster Randomized Controlled Trial Study. Arthrit Care Res. 2014 June; 66 (6): 810-816
Andrews LB, et al, Implementation of a pharmacist-driven pain management consultation service for hospitalized adults with a history of substance abuse. Int J Clin Pract. 2013 Dec; 67 (12): 1342-9.
June 17, 2017 : looking back hardly a day or two goes by since this year began when a question about medical marijuana or as we call it out here “marijuana” and what is going to happen next July when it becomes real is asked. Last month I was asked by a group of Nurse Practitioners to present on a topic I rarely speak about but fill prescriptions for often – BioIdentical Hormone Replacement Therapy. I like to use the term supplement instead of replacement but it really made me think about the tough upward climb this category has had and continues to have based on a few position statements from such groups as SOGC and NAMS.
Looking at the marijuana issue, never before have we seen a couple of ingredients leap onto the potential healthcare market with the claim to relieve or cure so many, many health issues. Never before have so many N of 1, anecdotal reports driven an entire category of mostly unproven therapies. Granted there are some valuable uses of the drug that have been used for years but many have been very overblown with the main selling point of “no one has died”.
Turning to my upcoming presentation, I started mulling over the studies that have shown for years the benefits and limitations of all types of hormone therapy that I have collected and still continue to collect on the topic. Speaking to the public on a subject is different than talking to medical professionals. I speak to both groups all the time on all topics. To narrow down an hour worth of meaningful, compelling, convincing data that flows easily on a medical treatment that is foreign to a professional group so that you don’t lose them is daunting.
If I present on a topic I have a clear conflict of interest with such as this, I always open with that and some literature from the other side of the argument. There is no problem here with BHRT as lots of naysayers exist. In truth, I have found there are as many cases of overblown promises with BHRT and there are complete opposite downplay of any proven benefits and exaggeration of adverse effects. A segment from Climacteric from just this year was the best I could find that slammed this type of therapy over a dozen sentences. We now see less of an issue with the term BioIdentical, since estrogen and progesterone are both found in the commercial prescription drug industry in Canada more and more in a bioidentical form, especially since the Women’s Health Initiative Study over a decade ago that effectively stopped conjugated equine estrogen and medroxyprogesterone acetate from being dispensed overnight. So at least Big Pharma has caught up with compounding in some ways.
I continue in my talk to disprove the issues just laid out from the climacteric slide: that hormones do pass predictably through human skin and give resultant increases in the body (given the correct fluid is tested), that the stability of the hormone in the right base is predictable, that saliva testing is legitimate and useful in showing levels of active hormones (especially for topically applied hormones), and that all hormone therapies have benefits and risks associated with them, regardless of what hormone therapy that entails.
Given the criticisms the WHI received, one thing we did find from the CEE/MPA regimen was the decrease in fracture risk. With the older average age of the subjects in that study and the lack of topical hormone or actual BHRT used, there is very little to pull from that study for this talk. There are however many studies that can and do show the benefit of BHRT. Most of these are smaller studies than we are used to in the prescription world. One point to take away though is we have seen a top seller in our prescription market fall away to nothing and the public is looking at us and asking how could we be so wrong all these years about something that was so blatantly clear in a study that it cut the study short? Evidence slowly grows on bioidentical hormones but is showing even to our commercial drug industry that it is a safe benefit.
The International Journal of Pharmaceutical Compounding published a three part study on the topic of BHRT. In this small study, surveys were given to women on HRT. The response rate was 70 on BHRT and 53 on synthetic hormone therapy. Each survey consisted of 15 questions that probed such topics as symptom relief, reasons for starting hormone therapy, side effects, age of starting therapy and type of therapy. In the areas of hot flashes, night sweats, sleep quality, dry skin/hair, vaginal dryness, foggy thinking, mood swings and decreased libido, bioidentical therapy outperformed synthetic therapy in all counts. In side effects from therapy, bioidentical was preferred over synthetic for side effects like difficulty sleeping, weight gain, breast tenderness, bloating, upset stomach, breakthrough bleeding, foggy thinking, mood swings and leg pain. Drowsiness occurred more frequently with bioidentical than with synthetic.
A huge concern with bioidentical and compounded hormones is the threat of cancer in hormone therapy. In 2008 a study that looked at over 80,377 post menopausal women, 2354 of them developed invasive breast cancer. Compared to the women that never used HRT, estrogen alone therapy was associated with a 1.29 fold relative risk, 1.69 with estrogen/progestagen and a relative risk of 1 with the estrogen/progesterone women.
In other studies we have seen the benefits from BHRT in areas of insulin resistance, blood pressure, lipids, endothelial function, arteriosclerosis, thrombotic risk, and neuroprotection. More and more we are seeing studies unfolding showing not only is BHRT a healthy and safe option for women of all ages but is also brings quality of life to these patients that they have lost since the Women’s Health Initiative Study came out. Saliva testing for topicals is also shown to be useful as topically applied hormones aren’t reflected in blood draws like oral is. Oral hormone therapy has shown itself to be an unhealthy route for women and topical application has proven itself to be the preferred choice longterm.
So yes, thank you Marijuana, or more correctly CBD:THC. Your very sudden rush to the market has been touted for virtually every medical issue going right now. There are definite benefits in areas such as pain, perhaps PTSD (and a few others) but completely untested and unproven “benefits” in so many other areas. It has shown us that there are areas like BHRT that we’ve been told we had zero proof for but really do have volumes of proof when we compare it to the complete lack of proof in marijuana for many of the areas it is being used for.
Orozco ,P. et al. Salivary Testosterone is associated with higher lumbar bone mass in premenopausal healthy women with normal levels of serum testosterone. European Journal of Epidemiology 16:907-912,2000
Wright, JV. Bio-Identical Steroid Hormone Replacement. Selected Observations from 23 years of Clinical and Laboratory Practice. Ann.N.Y.Acad.Sci. 1057:506-524 (2005)
Hofling, M, MD et al. Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. Menopause:The Journal of The North American Menopause Society. Vol 14, No.2, pp 183-190
Holtorf, MD. The Bioidentical Hormone Debate: Are Bioidentical Hormones (Estradiol,Estriol, and Progesterone) Safer or More Efficacious than Commonly Used Synthetic Versions in Hormone Replacement Therapy? Postgraduate Medicine, Volume 121, Issue 1, January 2009
Schwartz, E.T. MD. Hormones in Wellness and Disease Prevention: Common Practices, Current State of the Evidence, and Questions for the Future. Prim Care Clin Office Pract 35(2008) 669-705
Deleruyelle, LJ. Menopausal Symptom and Side Effects Experienced by Women Using Compounded Bioidentical Hormone Replacement Therapy and Synthetic Congugated Equine Estrogen and/or Progestin hormone Replacement Therapy: Part 3 . International Journal of Pharmaceutical Compounding Jan/Feb 2017 pp 6-16
Stephenson, K. MD FAAFP. Salivary Hormone Profile. International Journal of Pharmaceutical Compounding vol 8 no 6 November/December 2004
Wepler, ST. A Review of Bioidentical Hormone Replacement Therapy. International Journal of Pharmaceutical Compounding Vol.6 No.2, March/April 2002
One of the first topics he brought up was a story of a young Mississauga boy, Andrew, who had died from an apparent mix-up with a compounded medication.
The boy died of an overdose of baclofen after taking a prescription that was alleged to contain tryptophan for sleep. It was the first I had heard of the tragic story.
It is a scenario that mimics the worst possible case in the back of our heads each time we as pharmacists go to work each day.
As fallible human beings I consider us the strongest and weakest link in the chain of what has largely become an automated day—automated with humans that are capable of a momentary lapse of attention that can kill someone.
It not only focuses directly on errors but on almost any conceivable reason for them occurring
Almost exactly a month later, I am reading in Halifax’s Chronicle Herald of Ontario’s Health Minister Eric Hoskins desire to tighten the safety of his province’s pharmacy dispensing in the wake of this tragedy.
As part of that process he’s looking at how Nova Scotia has dealt with this issue (thechronicleherald.ca/novascotia/1416107-nova-scotia-pharmacies-lead-in-safe-medicine-practices, namely through an initiative called SafetyNET-Rx. ( http://www.safetynetrx.ca)
This story, of course, grabbed my attention, not only because I am a community pharmacist, but also because I also compound and live and practice in Nova Scotia.
I am further pulled into this story because the SafetyNET-Rx initiative mentioned was started at a former alma mater (St. Francis Xavier University in Antigonish, Nova Scotia), in part by a former classmate of mine from Dalhousie University College of Pharmacy (now Dean Neil MacKinnon at U of Cincinnati Winkle College of Pharmacy).
As a practising Nova Scotia pharmacist, I am fully involved with SafetyNET-Rx. Our pharmacy in Baddeck was part of the pilot project in 2010.
The Nova Scotia College of Pharmacists’ Standards of Practice (www.nspharmacists.ca/?page=standardsofpractice ) now outline that every pharmacy in the province must have a Continuous Quality Improvement (CQI) plan in place.
This is a requirement in the Practice Regulations to the Pharmacy Act of Nova Scotia. For the first time we now have a monitored, effective QCI process that tracks quality related events (QREs). It is the SafetyNet-Rx model we use now.
So what does this involve in our day-to-day work in the pharmacy? Mainly, anytime there is a QRE, we note it in a scribbler to be entered later into an online recording system.
These errors encompass everything that can go wrong, such as a prescription handed out for the wrong drug or directions or doctor (even if it exactly follows the actual prescription but was an unintended change).
Most of the recorded errors include mistakes made before the prescription actually gets to the patient’s hands. Every time we enter the wrong doctor, drug, strength or directions, it gets marked down. In a busy day we do the best we can to record these events but in reality some do get fixed and aren’t recorded.
These events are formally recorded online on the Community Pharmacy Incident Reporting site—ISMP (Institute for Safe Medication Practices).
Each pharmacy has its own username and login and can search based on several metrics the types of errors that occur, the days of the week they occur the most, who detected the error, contributing factors, degree of harm from the incident and what the error was—both for your pharmacy and combined aggregate of all pharmacies on the system.
It’s quite interesting to see these comparisons. All of this data is invaluable in helping to prevent future errors. Quarterly staff meetings are required and helpful in sharing this information.
Through this reporting system, we are keenly aware now of the most common source for errors, who is most likely to catch the error, why the error occurred and even when it is most likely to occur.
This allows us to plan staffing and make corrections that we would have normally made after a mistake is made; except now we can do it before the incident occurs.
We can see how we compare with all other community pharmacies and if a discrepancy occurs we can immediately make changes.
Knowing the most common errors prompts one to be extra careful in that field. For example, if you know your store has an inordinately high number of errors that involve number of doses dispensed compared to the aggregate, it becomes a focus until it is normalized.
If we find that many errors occur with incorrectly written prescriptions at the physician level, we would have that conversation with the physicians.
Along with this reporting system, there are several other checks in place. Many of these are done by any other pharmacy in the country. Staff emergency contacts are recorded, as are the numbers for all services used by the store from police and fire down to insurance, electrician, plumber, computer data and storage in case they are needed by any staff member.
Regular audits are done that range from removing outdated stock, adverse drug reaction reporting, monthly narcotic drug inventory reconciliation, equipment and facilities certification, adherence to standards of practice are recorded and annual staff performances.
Confidentiality agreements are signed, pandemic planning is completed, robbery and break-in procedures are made and reviewed and emergency response plans of all types are done (staff and customer accidents, fire, leaks, toxic spills and power outages).
For our pharmacy in Baddeck there were a few changes we made as a direct response from all of this monitoring. We determined the time of day and day(s) of week that we were most likely to see an error and we adjusted staffing levels to be heavier at those times.
We also determined a certain physician that had a higher probability of making an error when writing a continuation prescription for a drug that the patient was already on. This alerted us to pay extra attention to this occurring with this physician.
We also added another satellite computer in the pharmacy, not only as a reminder to document but to allow easier, daily documentation of events. When it wasn’t possible to do this we jotted them down for later entry.
Another interesting thing that came out from this was through the stringent narcotic self audits. We started noticing that a certain brand of medication was short one tablet in each bottle we were getting so these bottles were counted upon opening and the rep was alerted to the problem.
We also realized that the most common “near miss” incidents were incorrect quantity and incorrect dose. Special attention was brought to this during the quarterly meetings so extra attention on filling the script would prevent the problem again.
Future reports of quality assurance demonstrate the effect of these changes, new problem areas are found and new targets are made. Regular Medication Safety Self Assessments are done. This is a valuable tool that assesses the pharmacy’s overall ability to function safely based on many parameters and is done on a regular basis.
It is really an environment full of information that was floating there unharnessed before that monumentally helps to improve the safety of our patients when acted on.
If it seems like a lot of extra work in an environment that has very little down time, then you are correct. Personally though, I have always found a huge sense of calm knowing something extra was done to double check that a patient got what they were supposed to get when they leave my pharmacy.
The time involved though blends in with our work and is worth it. Time management is a skill that becomes greater as a result.
Getting back to the original patient we spoke of, Andrew, would this event had occurred if all of this were in place? It is difficult to speculate as the cause is before the courts right now.
One thing though is for certain, making an error is an opportunity to explore why that error occurred and make corrections so it won’t happen again.
In the December 1989 issue of the CAPSIL (The Canadian Association of Pharmacy Students and Interns), I wrote one of my first public articles (without the internet) on the topic of Medication Errors (http://capsi.ca/wp-content/uploads/2015/01/CAPSIL-JACEIP-1989-Dec.pdf ).
It is a subject that will never completely go away. It is a disservice to our patients to not act on each error as a learning experience. SafetyNET-Rx is an invaluable tool that really turbo charges your incident prevention and kudos to the Nova Scotia College of Pharmacists for implementing this requirement into their standards.
It not only focuses directly on errors but on almost any conceivable reason for them occurring. Hats off to my friend and Colleague Dean Neil MacKinnon for his role in its development. This standard is a huge leap forward that has caught the attention of the rest of the country.
I had the pleasure of corresponding with Andrew’s Mom earlier this year who contacted me ahead of a meeting with the Ontario College of Pharmacists Task Force where a proposal for medication error reporting was on the agenda. The College also contacted me ahead of this meeting to share ideas on the ISMP and my experience with it. Andrew’s Mom was glad to see movement on this system and its potential introduction in Ontario and thanked me for writing about this topic for the national audience of Canadian Pharmaicsts on the Canadian Healthcare Network. Hopefully some good comes out of this tragedy.
In 2015 I took four months to film a healthy grocery shopping tour with the help of a local filmmaker where I went through all areas of the grocery store to help people make healthy choices for themselves and their family. https://www.youtube.com/watch?v=cgEbpNL9PSg&t=1s
In the 40 minutes of video, the opening scene stresses the importance of cooking your own meals at home and knowing what to buy in order to do that.
This year I had the pleasure of attending a Diabetes Canada meeting in Sydney, N.S. It was a great morning of networking and meeting colleagues from all over Cape Breton. I asked one of the attendees at that meeting, Ann Marion Willis, a Registered Dietician who works with Atlantic Superstore if she was able to help out with an idea I had to do a cooking class for a small group. Out of that conversation I requested a location at the home economics room at Baddeck Academy with four stations to do a cooking class. They were gracious enough to allow us to use their facilities.
The plan is to have a parent or two bring their children in (from grade primary to grade 12) and show them how easy it is to make a meal that is healthy for them. Ann Marion has healthy recipes with nutrition information for all, a starter smoothie, a meal and dessert. She also demonstrated the preparation of the food. Space is tight but hopefully demand will drive further classes.
Studies that try to tie food intake with outcomes are notoriously plagued by problems that measure food consumption with questionnaires based on personal recall of consumption. Nevertheless there are studies that show the effect of how your food is prepared and what affect it has on your health. A 2007 study of 84 undergraduate students in Greece found that diet becomes less optimal when the student leaves home to live away, including eating out. Specifically, fresh fruits and vegetables and oily fish consumption dropped once they moved away from home.
The time taken to cook and cleanup after a meal has decreased by 50% in the last 40 years. While this number on its own isn’t very significant in determining anything, but it does reflect the availability of commercially prepared food, which is both quicker to prepare and cheaper because of its mass production. It stands to reason that both of these factors can lead to increased food consumption. In fact, countries that spend more time in food preparation correlate with a lower obesity rate. Again, there is no causality claimed here though.
In another study in the Journal of the American Dietetic Association (2006) that utilized food intake questionnaires in just under 1000 young adults, it was discovered that young adults that prepared food less claimed time restraints as a major determining factor. However in those that did report frequent food preparation did claim that they ate out much less often and were more likely to meet dietary objectives for healthy eating.
Learning to cook meals at home not just for yourself but your loved ones is one of the single most important things you can do to live a healthy life, when combined with physical activity. Teaching yourself and your children to prepare healthy meals at home controls much of what you consume and much of your overall health.
Two of the most common questions I get about my discontinuing of selling sugary beverages in September of 2014 is A) Did I notice a drop in income because of the lost sales of this line and B) Did I notice an increase in sales because of this move.
Before I stopped selling this line I would see perhaps $1000 on a good month in sales of these products. I don’t have a number of the extra sales made when customers came in to buy pop, juice, vitamin water, chocolate milk, or iced tea. This might be picked up by measuring a drop in sales beyond the regular amount of these beverages sold. Since there really wasn’t a drop in sales though, it is difficult to tell if these ancillary sales dropped or not.
One thing is for sure, the unexpected volume of free advertising it gave the store more than made up for anything lost on pop or any other extra product not being purchased with it. It elevated the reputation of the store to a destination where customers knew we were willing to try something bold to further their health, even if it meant less revenue.
One great offshoot of this event was the introduction it brought us to a key Canadian researcher, Leia Minaker at the University of Waterloo’s Propel Centre for Population Health Impact. She took notice of the activity in Baddeck and started a natural study to determine the effect this had in the selling of pop in Baddeck after that day in September. She collected sales data not only from us but from the two other major sellers in the Village and determined that there was no switching behavior in purchasing to these other outlets. The study was published in BMC Public Health in 2016. (Minaker LM, Olstad DL, MacKenzie G, et al. An evaluation of the impact of a restrictive retail food environment intervention in a rural community pharmacy setting. BMC Public Health. 2016;16:586. doi:10.1186/s12889-016-3281-9).
Another great find for me was Dr Yoni Freedhoff, one of this country’s most prominent voices not only on unhealthy marketing practices to everyone (especially children) but also on the larger topic of obesity.
After two and a half years I look back on this move as the best one I could have done for my Pharmacy. When I think of the doubt I had in the months or weeks leading up to this I now realize the worry was for nothing. In this day and age, we try to rock the boat as little as possible in our pharmacy models for fear of going out of business. I can assure you if by some stretch your pharmacy would close based on the lost sales of sugary beverages, then maybe you should be in a convenience store type of setting instead. If you know for a fact that the small amount of profit made on this loss leader (if any at all) won’t affect your store adversely, and you realize the huge price tag that the consumption of these beverages costs your country long term, what is the holdback in removing them from your business? After all, shouldn’t we be partly responsible for this cost to the healthcare system by continuing to sell liquid calories and in effect promoting them? When asked about other snack foods, which we have overhauled as well at Stone’s, my response is that this is my contribution to educating the public on one of the most common sources of extra calorie consumption starting with children and moving right on up to older adults. If you own a pharmacy, make a mark by taking your own stand on something that you know is causing harm to your patients. You’ll feel better for it and so will your business.
The front store of the pharmacy has traditionally been where the pharmacist and patient relationship grows to a level beyond where it would be with just prescription counseling alone. It affords to pharmacists a selection of products that empowers the lay public to take some sort control of their health in almost any way they choose. With certain selective issues (or perhaps a wider selection in their minds), they can bypass the waiting room of the physician, the poking and prodding, the embarrassing questions, the waiting at the pharmacy counter – all gone with just a wave of the hand from the OTC aisle to the pharmacist peering down to you from his or her stoop in the dispensary.
The general public questions this type of medical treatment very little, partially because of the level of trust that is consistently demonstrated towards pharmacists, or perhaps because most of what is available to choose from in this realm has been virtually unchanged in its ingredient list for decades. In fact I am willing to bet that if I were to walk through the aisles of my neighborhood pharmacy on the day I was born nearly 50 years ago, aside from a few struggles with brand names and a few recognized products that have been discontinued, the ingredient list on most items in the entire store would be much the same as my store today. This brings with it a level of trust in these products by the public, sometimes a false sense.
Back then many of these products were put there in the front store without a whole lot of randomized placebo controlled double blinded/crossover trials (RCT’s) that brought most of the prescription medications to market and back 50 years ago there was little debate as to their effectiveness. The pharmacist recommended it and you took it and it worked. That was that. The path that each product took to land on the shelves of your pharmacy each has a story and history of their own.
There is a growing concern that pharmacists are now selecting items for patients that have little backing scientifically. For example, one of these families of products, known as homeopathic, is one of them. Back 50 years ago you may have even spotted one of these in your neighborhood pharmacy. Now before I go any further I’ll end your guessing of my views of homeopathy: I don’t think it really does much of anything for anybody. For those of you still reading, because you’re in agreement of that last statement, just hold on a second. If we are slamming this mode of treatment because we feel the studies don’t back it or because there is nothing in the actual dosage form, that is fair enough. The supplement aisle is another category that brings about much criticism, and for the record, I have a different belief in this category (just not fanatical in like everyone should have all of them). But as “evidence based” practitioners, in all fairness we need to apply this to the entire store.
Applying our strong standard of evidence to everything else, we look with our magnifying glass at all other products: cough medicines, constipation relief, lice remedies, pain relief selections, antacids and reflux relief meds, skin creams, acne relief, teeth whitening (ok maybe not available in the 60’s), hemorrhoid relief, bug spray, lozenges, lip balm, and lots more. Can you quote or summarize the randomized controlled history for these categories? Perhaps can you find evidence against what you are recommending that product for? Acetaminophen for lower back pain? Cough syrup for someone with a common cold. You can check out a fuller explanation of these categories here .
So getting back to our original claim slammed against us: Why do we sell these items that obviously have some doubt as to their effectiveness? As a pharmacist I am always striving to supply what people want to use for their health as long as it does not harm their health in taking it. Secondly it should be effective. The order of these two is important. My community wanted organic food so that’s what I got in to sell at the pharmacy. Removed 12 feet of magazines and replaced it with organic, gluten free, non gmo. Does it harm them? No. Is it effective for what they are taking it for? Maybe. Maybe not. But it does not harm them.
When Cold FX was going through it’s court case on the claims it was making I voluntarily removed it from my shelves. When the case ruled in their favor I brought it back – much to the delight of my customers who had been asking for it for weeks and months. Is it safe – yes, and is it effective – who the hec knows. I push vaccines, but I also sell Muco Coccinum and stress that you cannot rely on that to prevent the flu or much of anything else. I sell probiotics but screen those with suppressed immune system who cannot safely take them. I ensure that it is used safely first and if it is effective for their gut health, immune health, skin health or mental health then so be it. I try to guide them with the studies I have available to me but first and foremost it must be used safely. That means the product won’t interact with their medication or medical condition or result in them omitting proper established treatment for their condition especially should it be serious or life threatening. No one should be curing cancer or treating their heart disease in this part of the store, but if they have a drug induced lowering of vitamin B12 then I’m their guy. If they are looking to prevent a cold they feel might be coming on with Zinc tablets then great (something I take).
The point of all this is most if not all of new drug research is targeted towards bringing new prescription medication to market, not OTC drugs. While it’s true that some prescription medication may trickle down to OTC status (and thankfully this should have RCT’s to back them up, which is great) not much groundbreaking in the OTC field happens for the most part. Recently I have seen a new product come out for varicose veins and one for vaginal dryness, but for the most part we are stuck with what we have out there, and it’s not an area where we test existing products on new indications, nor do we really go testing a lot of the current indications for existing products that they are sold for (perhaps with a few exceptions). Unfortunately the vitamin/supplement and herbal market is always pushing the boundaries of what science thinks will happen if you take pill A and what an RCT says. What this means is going forward we will be left with an aging pool of products, a number of which have questionable efficacy for the indication they are being sold for and a growing list of products that have the same backup. This pool may have some new additions here and there but the old standards stay around.
Complaining about a select group of these items such as homeopathy is noble, but is kind of two faced when we don’t slam other pharmacists that sell all the other products that have similar lack of actual evidence to back them up. Particularly when the pharmacist is following the law. Being a pharmacist is not being a doctor. We can now prescribe for minor ailments in my area, but the pharmacists today didn’t invent this front store they have available to them. A pharmacist’s recommendation may not always be the same as a doctor’s recommendation, or the same as another’s recommendation, but it should be as safe.
If you’re a prescriber or pharmacist, you owe it to yourself to check out the Atlantic Mentorship Network’s Prescribing Course – Safe Opioid Prescribing for Chronic Non-Cancer Pain. I had the pleasure of attending this course this weekend in Halifax, Nova Scotia. Although I had been trying to get to this amazing course for quite some time, my schedule finally permitted me to get there this year. In fact it was such an incredible learning experience I felt I should share it with you. As a disclaimer: I am a pharmacist, I have presented for the Mentorship program before, I have no financial interest in the program although I am involved with the planning of the program’s Fall Conference in Inverness Cape Breton this year. Other than that I’m just a fan of the Network.
Chaired by Dr. Peter MacDougall and Dr. John Fraser, this day-long event goes through pearls on what best practices are to deal with the average person with pain. This is not end of life pain or cancer pain, where boundaries are much wider. It is the tough world of dealing with pain at a time that threatens the potential of addiction more than we were aware of at any other time. It threatens safety of prescriber, patient, and the public. Even Dr. MacDougall claimed what many of us were told years back when dealing with narcotics: that we used to think that as long as there was still pain, the chance of addiction was extremely rare. The Nova Scotia College of Physicians and Surgeons are quite active now in reducing the narcotic load in our patients, as are the other provinces in Canada as the wave of overdoses washes eastward. They have adopted the CDC guidelines for treating this type of pain, which includes more of an emphasis on non-narcotic and non-drug.
As someone who feels the burn of the “online” world of alternative treatments and skeptics’ treatment of them, believe me it was refreshing to be in an entire room full of 40 legitimate practitioners embrace whatever works for their patients. I have commented on this phenomenon before and it was evident here again. Terms like physiotherapy, chiropractic, massage, TENS, acupuncture, qigong, yoga and other terms used side by side are embraced by physicians as treatments that have clinical results that they may or may not have success with. I have been working as a pharmacist for almost 24 years and the most important clinical pearls I picked up were:
-If someone claims to be travelling away and needs their Narcotics early ask them when, how are they getting there and where are they staying. This allows you to call contacts (landline) while the patient is sitting in front of you in the office and gives an opportunity to ask (demand) to see plane/bus/train tickets.
– There are many Addiction Risk Assessment tools that really don’t have any evidence to back them up but they can be clinically effective tools in seeing who might be at the highest risk for addiction in the future and who may require special attention going forward with their therapy.
– Although many patients in our patient records claim to be allergic to morphine, this “allergy” may actually be a normal pruritis side effect from the morphine and not an allergy at all.
-An increased request for more narcotic dosing may occur after a previous increase in dose for many reasons. It may be from hyperalgesia from the narcotic causing more pain. It may be from the increased activity that the pain relief allowed – which causes more pain. The concepts of pseudoaddiction, tolerance, pseudotolerance, opioid withdrawal, failed opioid trial and chemical coping are all important factors to consider.
-One way to realize if an aberrant behavior more serious or less serious is to ask yourself, “I would never think to do that” or “I wouldn’t even know how to do that”. If the answer is “yes”, then it is most likely a more serious behavior.
– Safety of the prescriber is paramount
– UDT or Urine drug testing (preferably onsite) and a patient contract should be a standard practice for your opioid patients. It should be kept in mind that not only is UDT an important piece to the overall puzzle, its limitations should be kept in mind.
– “It is the information and not the story” that should be considered with abberant behavior. Why you ran out early is less important than the fact that you ran out early.
– Evidence on opioid rotation is primarily anecdotal but it can be an important method to reduce narcotic load after a failed opioid trial.
– As much as the goal of no narcotics beyond 3 months for this pain is ideal, we will always see these medications given. The goal of “no pain” is not a concept we entertain, and function should always come before pain relief. PRN doses of narcotics on top of long acting narcotics only focuses on the pain relief and not the function. Long acting narcotics are perfectly ok for initiation of narcotics rather than the tried and tested method of “start with short acting meds then convert to long acting”. Patients will not feel the same on these two types of meds and it might be counter productive to have the patient switch to long acting and not feel as well as the short acting med made them feel.
– Determining the goals of the patient and the expectations of treatment are important.
If you can’t make it to this annual event (now in its 18th presentation), you should get to a similar program in your area. This one gets definite kudos from me. Well done!
Graham MacKenzie Ph.C.
When I graduated from Pharmacy school in 1993, topically applied preparations for pain relief were limited to lidocaine and capsaicin, or so I was told up to that point. I was also taught that narcotics were safe not only for short term pain relief but also for long term pain that was non palliative and non cancer related and that addiction was rare in cases where total pain relief had not been reached yet. Medication is a constantly evolving and changing world. 23 years has passed and all of this has changed in a drastic manner.
It’s difficult to know exactly how it all started, but many in the medical community like to lay blame on the shoulders of a company called Purdue that had its beginnings in New York City as a relatively small pharmaceutical firm in the early 1950’s when it was purchased by two psychiatrist brothers, Mortimer and Raymond Sackler. The success of OxyContin from this company generated billions of dollars in revenue and made the Sacklers one of the wealthiest families in the country. Unfortunately, we began to see a trend happening where claims of this company and the aggressive and inappropriate marketing practices resulted in the alarming abuse and trafficking of this medication over decades of use. The company had to pay 635 million dollars after executives plead guilty.
You’d think that would have been the end of it. However the Mundipharma associated foreign corporations are agressively marketing this same medication worldwide with no plans to scale back. They also are running training programs to physicians in these countries urging them to overcome “opiophobia” and to just go ahead and write for these painkillers. They also have campaigns urging patients to take what their doctors prescribe to them.
The issue now is we have created an entire continent of addicts who would not normally have been there without these recommendations. For example, Jane Doe gets in a car accident. She has undeniable pain from this and it is not handled with NSAIDS. She is given a narcotic based on the recommendations from companies like Purdue who claim their studies show this is a safe medication to prescribe in this patient. In a little while Jane needs a higher dose of the medication and after not too long, despite her repeated denials, is addicted to painkillers. She then is unable to get a continuous supply of the drug from her doctor who now recognizes the problem. She starts to purchase the medication off the street. Her addiction becomes stronger as her supply and quality of the medication becomes more and more questionable. She then finds herself injecting to keep up with her addiction. In the last number of years, she has lost her job, her husband, her children, her home, car, money, friends, and everything she owns is in a small bag that she uses as a pillow because she lives on the streets with a sole purpose of seeking her next supply of fentanyl.
Is this scenario typical of everyone on narcotics? Of course not. If you walked down Vancouver’s downtown Eastside and asked random passersby what their story is, you might hear this one. Canada has recognized this in a west – east manner this year. Canada’s largest mental-health/addictions hospital, the Centre for Addiction and Mental Health in Toronto called on Ottawa in November to remove these high dose opioids from the market and to launch a review of prescription painkillers across Canada.
In fact, in the last 4 years, the number of opioid prescriptions dispensed per 1000 population has decreased in the United States whereas in Canada the number has more or less remained the same over that time frame. The provinces in Canada have been steadily spending more and more each year on opioid addiction. Not surprisingly, BC has lead this spending. PEI and NB are 2nd and 3rd behind them surprisingly. NS is near the bottom of the list. Towards the end of the year, Nova Scotia’s chief medical officer, Dr. Robert Strang, made a statement where he wanted the provinces’ physicians to ween patients back from current prescribed levels of narcotics exceeding the 90 mg per day of morphine and to keep to max of 50 mg if possible. He also wants long-term fentanyl patients backed off this drug in an effort to fit in with upcoming guidelines. The Nova Scotia College of Physicians and Surgeons is endorsing the CDC guidelines for prescribing opioids.
Lately in the news on the west coast we had a story in the news of 13 overdose deaths in one day making emergency kits a necessity. Nova Scotia Pharmacists are now able to dispense rescue kits of naloxone for overdose and these kits are becoming more available as the awareness of the antidote and education spreads.
The CDC promotes the prescreening of patients to avoid addiction. Overdose concerns are more prevalent with those over 65 years of age, history of overdose, substance abuse disorder (including alcohol), history of depression, renal or hepatic impairment and sleep-disordered breathing. Any patient may be considered at risk for overdose if they combine opioids with benzodiazepines, on a longterm formulation or especially just starting this medication, on an opioid for longer than 3 months, or on more than 100 morphine mg equivalents. Addiction is more prevalent with this level of morphine equivalents as well as being on the opioid longer than 3 months.
Nova Scotia’s Dr. Mary Lynch has gone on the record as not being in favour with these strict guidelines and claims that there are many of her patients where there simply is no alternative drug for them. Many physicians are unclear as to what they are supposed to use to control the pain of their patients.
Unfortunately later this year we heard of a list of Doctors flagged by Ontario’s Ministry of health because they were prescribing the equivalent opioid dose of 150 Tylenol 3’s daily for some patients. 86 physicians were the target of this probe.
The recommendations include such non pharmacologic modalities as cognitive-behavioral therapy, exercise therapy, complimentary medicine (like yoga, meditation and acupuncture). Nonopioid analgesics recommended include acetaminophen, NSAIDS, Cox-2 inhibitors, anticonvulsants like gabapentin or pregabalin, and antidepressants like tricyclics and serotonin and norepinephrine reuptake inhibitors. Other therapies involve epidural injection and biofeedback.
With such a sense of urgency and recommendations of treatments not normally seen by physicians in general medicine, one would expect that physicians would be open to topical pain relief. In speaking to physicians I have found a friendly acceptance but a definite hesitance in writing for these compounds. These compounds are new to them and contain such familiar oral ingredients as ketamine, ketoprofen, clonidine, gabapentin, and lidocaine. They may also use lorazepam, carbamazepine, baclofen, cyclobenzaprine, dextromethorphan, and others. A recent article written by myself and a local palliative care doctor covers these ingredients. Check it out here.
This is a tremendous opportunity to reduce opioid use and improve pain relief. As I have seen from physicians that have tried this and seen it working in their patients, confidence comes with numbers and experience. The lack of side effects, interactions and lowered dose is something they like. Contact a compounding pharmacy and ask them more.
The world has a tremendous love of grilling. Most would think of it as a North American tradition, but in reality, there are many countries around the world that commonly utilize this unique form of food preparation. Australia, Argentina, Brazil, Japan, India, Jamaica and Vietnam all show a strong affinity for grilling. It would not be uncommon for many of us to recall growing up eating food prepared this way on occasion. We never gave it a second thought. Nothing could be more natural in food preparation: outside, over the open heat, with constant attention to detail, easy on the environment, and simple. It is almost caveman like.
But wait. Cavemen lived to an old age of 20 or 30 years of age if they were lucky. I suppose there are many reasons we could discuss for this change in life expectancy, the least of which is food preparation methods. However it is hard to navigate through a Summer season without coming across a news story on the harmful, cancer causing effects of grilling. Well laid out logical explanations of carcinogens created in the high heat process of cooking this way attempt to lead the public into a conclusion that each barbequed meal will bring you one day closer to cancer.
What evidence base is available to us to A) Show that these products are indeed created with grilling, B) That these products are carcinogens and C) That grilling does indeed result in increased cancer rates. In truth, the creation of heterocyclic amines (HCA’s) and polyaromatic hydrocarbons (PAH’s) not only occurs by the barbequing process, but we also know that these products are clear carcinogens. These two are now established fact. However the “evidence based” answer we are looking for is “does the consumption of meat that is barbequed lead to a higher incidence of cancer?” Answering this avoids jumping to conclusions when you have data that appears to lead to a conclusion without evidence to back it up.
Another fair question is if there is an increased incidence of cancer in a population that consumes more of this type of food, is it because of the HCA’s and PAH’s from the food or is it simply because of the increase in meat consumption – something that has shown to increase cancer rates. Red meat on its own may contribute to increased cancer rates by contributing to N nitroso compound (NOC) exposure, and this is dose dependently associated with the amount of red meat in the diet . There are also other proposed causes of cancer from red meat such as heme iron and nitrate/nitrite levels We have seen some studies that appear to show an increase in cancer rates when rats are given a diet that has HCA’s and PAH’s but as is often done with thee studies, the levels of ingestion were much higher than you would experience in a normal diet. Extrapolating this to humans isn’t simple. This is yet another pitfall in evidence based medicine: animals vs human exposure.
Having said this, there are some studies that show a correlation specifically with high heat cooking and certain types of cancer. For example we have seen prostate cancer not correlate with total meat but very well done meat shows an increase in this cancer as opposed to no meat intake . Pancreatic cancer is associated with increased overall meat intake as well as red only and high temperature meat cooking . One huge drawback of these longer term studies include the concept of self-reported dietary diaries, which can be inaccurate.
So, where does this leave us? The next time you hear a story on the news or read an article on the dangers of barbequing and cancer, how should you respond? I throw this food item in the same bin as nonorganic and GMO, there are small pockets of evidence that say MAYBE there MIGHT be SOME benefit in your body but if you are looking for definitive answers like the ones we give when we say “don’t drink turpentine”, we just aren’t there yet. You probably are more likely to be harmed from undercooking the meat, getting a parasitic infection , consuming preserved meats or getting a metallic bristle ingested. There has been a suggestion that you should eat twice as much vegetables as grilled meat, but that should probably go for any meal. It is hard to argue against a more veggies less meat diet in overall health. Also frequently turning the meat on the grill will help reduce the amount of HCA’s produced. If you have a choice and are looking to reduce exposure as much as possible, steering away from charcoal and towards gas grilling may be preferred. In fact, there is some evidence that the particulate matter in the indoor air of barbeque restaurants or if you are a neighbor of such a restaurant might be just as bad to your health based on measured air-born levels of hazardous agents (but again, no longterm proven effects). As an aside, if you do choose to grill, you may want to take our lead this week when the Home Hardware in Baddeck which the Drug Store owns, pulled all Metallic Bristle Grill Brushes off the shelves and stopped selling them for good. We suggest you do also for your good health. There is however no harm or shame in choosing to eat a certain way or avoid a certain food on the basis that it might have the potential to harm you, as long as you are eating a balanced diet.
Graham MacKenzie, PhC